Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 10/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397288 | 0.87 | PIK3CD (0.42) | PIK3CDPIK3CBPIK3CA | |
| SCHEMBL19836871 | 0.86 | PIK3CD (0.52) | PIK3CDMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL19836878 | 0.85 | PIK3CD (0.47) | PIK3CDMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL17397131 | 0.82 | PIK3CD (0.44) | PIK3CDMAPTPIK3CBPIK3CADPP4 | |
| SCHEMBL17401032 | 0.81 | PIK3CD (0.56) | PIK3CDL3MBTL1PIK3CBPIK3CAKDM4E | |
| SCHEMBL17397094 | 0.81 | PIK3CD (0.56) | PIK3CDL3MBTL1PIK3CBPIK3CAKDM4E | |
| SCHEMBL19836893 | 0.81 | PIK3CD (0.47) | PIK3CDMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL19836910 | 0.80 | PIK3CD (0.48) | PIK3CDMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL17331860 | 0.79 | TRPV1 (0.40) | PIK3CDMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL17397077 | 0.78 | PIK3CD (0.55) | PIK3CDMAPTPIK3CBPIK3CADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224248-B1 | CERTAIN PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2021-05-05 | — | — | EP | disclosed |
| CN-107207441-B | Protein kinase inhibitors | 上海复尚慧创医药研究有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-10328060-B2 | Certain protein kinase inhibitors | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-9944639-B2 | Quinolizinone derivatives as PI3K inhibitors | LUPIN LIMITED (IN) | 2018-04-17 | — | — | US | disclosed |
| US-20180036293-A1 | CERTAIN PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-02-08 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2017-05-18 | — | — | US | disclosed |
| EP-3164400-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | Lupin Limited (IN) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001855-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016001855-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | LUPIN LIMITED (IN) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036293-A1 | CERTAIN PROTEIN KINASE INHIBITORS | AKT1, PIK3CA, AKT3 | PIK3CD 6/4885MAPT 2101/4885RAB9A 1630/4885 |
| US-10328060-B2 | Certain protein kinase inhibitors | AKT1, PIK3CA, AKT3 | PIK3CD 6/4885MAPT 2101/4885RAB9A 1630/4885 |
| US-20170137421-A1 | QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS | PIK3R5, PIK3R1, PIK3R4 | PIK3CD 5/4885MAPT 1030/4885RAB9A 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.